OTHER FUNCTIONS ENUMERAL "PHASE I, TOPIC 309, DETECTION OF MULTIPLE ANALYTES FRO

癌症是影响世界各地数百万人生命的主要死亡原因。这是一种复杂的疾病，可能需要多因素测量才能更早、更准确地诊断和患者分层。组织活检和细针抽吸物通常在临床上收集，但现有的多分析技术平台缺乏从单一样本中提取有意义的信息的设备。 该方案的目标是表征用于临床样本多分析物测量的数字S技术，并设计用于第二阶段的自动化原型系统。数字S平台非常适合于小样本的测量，因为它可以接受和分析来自身体任何组织的任何大小的细胞样本。该系统将以市面上可用的试剂为特征，并在活检样本上进行测试，以测量分泌蛋白、表面标记和基因表达。 随着与癌症相关的死亡率和每年采集的大量临床样本，小组织样本分析技术的进步有可能促进对癌症进展的了解，并为诊断和治疗范例打开新的大门。

Cancer is a leading cause of death that affects millions of lives across the world. It is a complex disease that is likely to require multifactorial measurements for earlier and more accurate diagnosis and patient stratification. Tissue biopsies and fine needle aspirates are commonly collected clinically, but existing multi-analyte technology platforms are ill-equipped to derive meaningful information from single samples. The goal of this proposal is to characterize Enumeral¿s technology for the measurement of multiple analytes on clinical samples and to generate a design for an automated prototype system to be used in Phase II. Enumeral¿s platform is ideally suited for the measurement of small samples, as it can accept and analyze cell samples of any size from any tissue in the body. The system will be characterized with commercially available reagents and tested on biopsy samples to measure secreted proteins, surface markers, and gene expression. With the mortality associated with cancer and the sheer volume of clinical samples taken on an annual basis, the advancement of technologies for the analysis of small tissue samples has the potential to advance the understanding of cancer progression and open new doors for diagnostic and treatment paradigms.